The estimated Net Worth of Stephanie Morley is at least $532 Tisíc dollars as of 12 April 2021. Dr Morley owns over 805,000 units of Zomedica Pharmaceuticals stock worth over $249,063 and over the last 7 years he sold ZOM stock worth over $0. In addition, he makes $282,703 as Consultant at Zomedica Pharmaceuticals.
Dr has made over 3 trades of the Zomedica Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 805,000 units of ZOM stock worth $273,700 on 12 April 2021.
The largest trade he's ever made was exercising 805,000 units of Zomedica Pharmaceuticals stock on 12 April 2021 worth over $273,700. On average, Dr trades about 234,833 units every 185 days since 2018. As of 12 April 2021 he still owns at least 1,959,580 units of Zomedica Pharmaceuticals stock.
You can see the complete history of Dr Morley stock trades at the bottom of the page.
Dr. Stephanie Laine Morley D.V.M., DVM is the Consultant at Zomedica Pharmaceuticals.
As the Consultant of Zomedica Pharmaceuticals, the total compensation of Dr DVM at Zomedica Pharmaceuticals is $282,703. There are no executives at Zomedica Pharmaceuticals getting paid more.
Dr DVM is 46, he's been the Consultant of Zomedica Pharmaceuticals since . There are 10 older and 2 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.
Stephanie's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48108.
Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers a Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include: